Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 25, 2023

Manufacturing Processes in Cell and Gene Therapy with Emily Moran (INTERPHEX 2023)

Emily Moran, senior vice-president of vector manufacturing and supply chain at The Center for Breakthrough Medicines, talks about manufacturing processes for viral vectors in the cell and gene therapy space, and more.

Emily Moran, senior vice-president of vector manufacturing and supply chain at The Center for Breakthrough Medicines, talks about manufacturing processes for viral vectors in the cell and gene therapy space. She also discusses complications and standardizations in manufacturing processes, as well as how automation and digitalization may impact the future of cell and gene therapies.

For more INTERPHEX 2023 video content, check this page for updates.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.